AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

therapeutic effects. Over the past six months, AbbVie has announced plans to significantly expand its API manufacturing capabilities and capacity in the U.S. In September 2025, AbbVie broke ground on the first phase of this investment, a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology and oncology products from Europe and Asia to the U.S.With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., ...